Fig. 8
From: TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma
In vivo activity of hit 17 in MM xenograft models. In vivo growth of NCI-H929 and AMO-1 xenograft intraperitoneally treated with hit 17 at dose of 4 mg/kg. Average tumor volume of NCI-H929 (A) and AMO-1 xenograft (B) ± SD (5 animals per group) is shown, *p > 0.05. H&E staining (C and D, 40x) and IHC evaluation of Ki67 (E and F, 40x) of retrieved tumors from NCI-H929 xenograft after hit 17 treatments. G WB analysis of p-CHEK1, p-CHEK2, cleaved-caspase-3 in lysates from a representative NCI-H929 retrieved xenografts. GAPDH was used as control. H WB analysis of DNA ligase I, TERT, PARP1, and RAD51 in NCI-H929 and AMO-1 retrieved xenografts. I Representative RT-qPCR of TERRAs from three NCI-H929 and AMO-1 xenograft samples after hit 17 treatments. *P <0.05; **P<0.01; ***P <0.001; ****P<0.0001